
Alpine Immune Sciences ALPN
Quarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences EV - Enterprise Value 2011-2026 | ALPN
Annual EV - Enterprise Value Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 363 M | 277 M | 291 M | 63.4 M | 91.7 M | 70.2 M | 15.9 M | 23.4 M | 16.5 M | 94.3 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 363 M | 15.9 M | 131 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
395 M | $ 2.8 | -3.69 % | $ 158 M | ||
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
ANI Pharmaceuticals
ANIP
|
1.91 B | $ 80.89 | -1.35 % | $ 1.56 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Amgen
AMGN
|
145 B | $ 341.41 | -0.45 % | $ 183 B | ||
|
Aeglea BioTherapeutics
AGLE
|
725 M | - | - | $ 1.01 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.68 | 3.88 % | $ 16.8 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.23 | -1.01 % | $ 7.77 B | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Aptose Biosciences
APTO
|
10.8 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | ||
|
Biogen
BIIB
|
28.3 B | $ 177.21 | 0.61 % | $ 25.8 B | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
2.59 B | $ 28.43 | -2.94 % | $ 2.34 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
726 M | $ 224.26 | 0.14 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
-18.3 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
BioNTech SE
BNTX
|
-6.64 B | $ 115.04 | -1.49 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
3.22 B | $ 9.65 | - | $ 1.52 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
6.02 B | $ 68.78 | -0.5 % | $ 9.2 B | ||
|
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | ||
|
CASI Pharmaceuticals
CASI
|
1.08 B | $ 1.01 | 1.6 % | $ 137 M | ||
|
Catalyst Biosciences
CBIO
|
38.1 M | $ 9.79 | -3.55 % | $ 644 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-9.74 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
2.15 B | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
115 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 4.0 | -3.61 % | $ 8.7 B | ||
|
Amneal Pharmaceuticals
AMRX
|
1.72 B | $ 14.0 | -0.78 % | $ 4.33 B | ||
|
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | ||
|
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Cerus Corporation
CERS
|
425 M | $ 2.28 | -1.94 % | $ 421 M | ||
|
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K |